Among CHEK2 p.I157T patients with myeloid malignancies, 40% (8/20) had a previous solid organ malignancy; 15% (3/20) had surgical treatment only, and 25% (5/20) had chemotherapy or radiation, one of whom had radiation for an antecedent Hodgkin lymphoma. The gene discussed is CHEK2; the disease is myeloid neoplasm.